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Introduction
Melanoma is the most aggressive form of skin cancer. In contrast to most other tumor types, the annual incidence of melanoma continues to rise, suggesting that it will be an increasingly important public health issue in the future (1, 2). One of the most common and devastating complications of melanoma is the development of metastases to the central nervous system (CNS). Lung cancer, breast cancer, and melanoma are the three most common sources of brain metastases (3) . As melanoma is much less prevalent than lung or breast cancer, this reflects the heightened propensity of melanoma to metastasize to the brain-the highest among common malignancies. Up to 75% of stage IV melanoma patients will develop brain metastasis(es) during the course of their disease (4) . The brain is often the first, and sometimes the only, site of disease progression in patients treated with systemic therapies (5) . While multiple therapeutic modalities are used in patients with brain metastases, the median survival for these patients is ~4 months from diagnosis, and >50% of melanoma-related deaths are caused by brain metastases (6) (7) (8) (9) (10) .
Ipilimumab and dabrafenib are two new therapies approved by the US Food and Drug
Administration for treating metastatic melanoma, but they showed only modest activities in patients with brain metastases, with median progression-free survivals (PFS) reported to be 1. 4 and ~4 months, respectively (11, 12) .
The treatment of patients with metastatic melanoma is evolving rapidly due to an improved understanding of the molecular underpinnings and heterogeneity of this disease. While there is a critical need for more effective treatments for melanoma patients with brain metastases, at this time there is very little information available about the molecular characteristics of these tumors.
Broad molecular profiling studies in other tumors, such as breast cancer, have shown that tumors that metastasize to the brain can have distinct molecular features from tumors that metastasize to Author Manuscript Published OnlineFirst on May 6, 2014; DOI: 10.1158/1078-0432.CCR- other sites (13) . Other studies have demonstrated that brain metastases and extracranial metastases within individual patients can show marked molecular differences, including those in targetable pathways (e.g., EGFR in lung cancer (14-16)). In melanoma, previous studies examining individual proteins (e.g., P-STAT3, SOCS1) or pathways (e.g., PI3K/AKT) have identified significant differences in their expression in brain and extracranial metastases, albeit in specimens from different patients (17) (18) (19) . More recently, an immunohistochemical study of nine patients for MAPK and PI3K/AKT pathway activation markers demonstrated that P-AKT expression can be higher in brain metastases compared to extracranial metastases from the same patient (20) . A broader transcriptional analysis of patient-matched brain and extracranial melanoma metastases also recently identified genes with differential levels of expression between brain and extracranial metastases, although this analysis failed to identify any significantly enriched pathways (21) .
Together these previous studies support the rationale for broader profiling of brain metastases in order to improve our understanding of the molecular features of these tumors and to support development of rational therapeutic approaches. Here we report the results of high-throughput molecular analyses of matched pairs of melanoma brain and extracranial metastases from patients who underwent surgery for both types of tumors over the course of their disease as part of their standard clinical care. The assessable tissues were analyzed for known recurrent DNA hotspot mutations, DNA copy number variations (CNV), whole genome mRNA expression patterns, and the activation and expression of protein signaling networks. Analysis of the results from these different platforms supports that while patient-matched brain and extracranial metastases overall are quite similar, significant differences are observed in targetable pathways in brain metastases. In particular, our broad molecular analysis and early functional studies add Author Manuscript Published OnlineFirst on May 6, 2014; DOI: 10.1158/1078-0432.CCR- to previous data supporting a critical role for activation of the PI3K/AKT pathway in these tumors. Table S1and S2 ). CNV and gene expression data from these samples are available at Gene Expression Omnibus (GEO) database (accession number GSE50496).
Materials and Methods

Clinical Samples
Sample Processing
For each tumor sample used for analyte (DNA, RNA or protein) extraction, a hematoxylin and eosin (H&E)-stained slide was prepared and reviewed by a pathologist (AJL, KA). Regions containing 70% or more viable tumor cells were identified. To isolate tumor tissue, the marked H&E slide was used to guide macrodissection of the matched tissue block. Extraction of DNA (QIAamp DNA FFPE Tissue kit, Qiagen), RNA (22) , and protein (23) from the dissected tumor samples was performed as previously described.
Mutation Detection
Genomic DNA samples extracted from FFPE tissues were genotyped using Sequenom mass array for the presence of any of more than 154 previously reported somatic hotspot mutations Table S3 ) by the MD Anderson Characterized Cell Line Core facility as previously described (24) .
Copy Number Determination
Molecular inversion probes arrays (Affymetrix) (25) were used to identify genome-wide CNV in DNA extracted from FFPE tumor samples. DNA from normal tissues of the same patients was used as controls. Quality scores were calculated for each sample and samples with poor data quality were removed from further analysis. CNVs were then segmented using the SNP (single nucleotide polymorphism)-FASST2 (Fast Adaptive States Segmentation Technique) algorithm in Nexus 7.0 (Biodiscovery). For segmentation, the threshold (log2 scale) for a single copy gain/loss was set at +/-0.3, and a high copy gain or a homozygous loss at +/-1.2. Two-tailed Fisher's exact test was used to compare CNV frequency between brain and extracranial metastases.
Gene Expression Profiling
Total RNA was extracted from frozen tumors and subjected to whole-genome gene expression profiling using HumanHT12 v4 beadchip arrays (Illumina). RNA amplification (TotalPrep RNA Amplification Kit, Life Technologies), array hybridization, and data acquisition were performed at the University of Texas Health Science Center at Houston Microarray Core laboratory. Gene expression data were quantile-normalized and analyzed using BRB-ArrayTools (26) . P-values for gene expression differences between brain and extracranial metastases were determined using a random variance model (27) .
Reverse Phase Protein Array
Research. Protein lysates extracted from frozen tumors were analyzed by RPPA at the MD Anderson Functional Proteomics Core facility as previously described (22) . A detailed description of the RPPA method and data normalization is available at the core facility's web page 1 and antibodies used for RPPA are listed in Supplementary Table S4 . Heatmaps were generated using Cluster and Tree View (28) . P-values for protein expression differences between groups were determined in BRB-ArrayTools using a random variance model. Slides with insufficient viable tumor tissues were excluded from analyses.
Immunohistochemical Staining
Results
Hotspot Mutation Analysis
Sufficient DNA was available from matching resected brain and extracranial metastases from 16 patients to undergo Sequenom mass-array analysis for a panel of 154 recurrent hotspot mutations previously reported in cancer (Supplementary Tables S2 and S3 ). For two samples with lowconfidence BRAF V600E calls, the presence of mutant BRAF V600E protein was validated by 1 http://www.mdanderson.org/education-and-research/resources-for-professionals/scientific-resources/core-facilitiesand-services/functional-proteomics-rppa-core/index.html immunohistochemical (IHC) assay. Sequenom and BRAF V600E IHC analyses of the brain metastases detected BRAF V600 mutations in seven (44%) and NRAS Q61 mutations in three (19%) patients. CTNNB1 S45 mutations were found in two brain metastases (13%), one of which contained a concurrent NRAS Q61 mutation (Table 1 ). Brain metastases and matched extracranial metastases were 100% concordant for BRAF mutation status among the 16 pairs. For NRAS, a Q61H mutation call for one sample (extracranial metastasis of patient 17) was indeterminate because the mutation was detected in only one of the two technical replicates; all other paired samples were concordant. CTNNB1 S45 mutations were 100% concordant among the 16 pairs of matched metastases. These results suggest identical patterns of the recurrent hotspot oncogenic mutations tested in melanoma brain and extracranial metastases in individual patients.
Copy Number Variation Landscape
CNVs were identified in matched tumors using molecular inversion probe (MIP) arrays. After quality control analysis, CNV profiles were obtained from 10 pairs of matched brain and extracranial metastases. Frequent (>35%) gains of large chromosomal regions in 1q, 6p, 7p, 7q, 8q, and 17q and losses in 6q, 8p, 9p, 9q, 10p, and 10q were observed in the brain metastases compared to normal germline DNA (Fig. 1A) . The same CNVs were detected at similar frequencies in the matched extracranial metastases (Fig. 1A) . Of note, CNVs in these regions have previously been reported in melanoma (29, 30) . To compare CNV profiles between individual pairs of tumors, unsupervised hierarchical clustering was performed using the copy number (CN) data for the 20 matching samples. In the resulting dendrogram, the 10 brain metastases did not cluster together, indicating no broad similarity in CNV profiles among brain metastases (Fig. 1B) We then compared the frequencies of CNVs between matched brain (N=10) and extracranial (N=10) metastases to identify genes with significant CN differences. Forty-one genes on chromosomes 13 and 15 were found with significant CN difference (P<0.05) between brain and extracranial metastases (Supplementary Table S5 Table S6 and Fig. 1C) . The results showed that CNV frequencies in these 13 genes were similar between matched brain and extracranial metastases (Fig. 1C) , although CNVs between matched samples were often discordant in some genes (e.g., MITF, Supplementary Table S6) .
Gene Expression Profiling
Whole-genome mRNA gene expression profiling was performed on mRNA from frozen tissue samples for 27 brain metastases and 25 extracranial metastases, including six pairs of matched samples. All patient-matched samples (N=12, Supplementary Table S2) clustered with each other in hierarchical clustering of gene expression data ( Fig. 2A and Supplementary Fig. S1 ), suggesting highly concordant gene expression patterns overall between matching brain and extracranial metastases from individual patients. Table S6 ), patient 03 was the only patient with available gene expression data. In this patient PTEN expression in the extracranial metastasis was much higher than in the brain metastasis ( Supplementary Fig. S2 ).
Paired t-testing of matched brain and extracranial metastases identified 86 genes with significant differences in expression (P<0.01 and fold change of mean expression >1.5, Supplementary Table S7 ). There was no overlap between the 86 genes and the 41 genes that demonstrated at least one-copy change between matched brain and extracranial metastases (Supplementary Table   S5 ). Analysis of the 86 genes in the unmatched brain (N=21) and extracranial (N=19) metastases
showed that three genes also demonstrated significant (P<0.05) differences in expression in this independent cohort of patients: SGK3, SGSM2 and ELOVL2. All three genes were overexpressed in the brain metastases in both the matched (Fig. 2C) and unmatched (Fig. 2D ) sample sets. The significant differences in the matched samples were confirmed by quantitative RT-PCR ( Supplementary Fig. S3 ).
Protein Expression Profiling by Reverse Phase Protein Array
Research. 
Reverse-phase protein array analysis (RPPA) was performed on protein lysates extracted from frozen tumor tissue to quantitatively measure the expression levels of total-and phospho-proteins (Supplementary Table S4 ). After quality control analysis, expression data for 152 proteins were available for nine brain and 20 extracranial metastases, which included seven matched pairs of samples. Unsupervised hierarchical clustering of the data for all 152 proteins for the full cohort of samples (N=29) found that six of the seven brain metastases clustered with matching extracranial metastasis from the same patient (Fig. 3A) . Thus, overall similar patterns of protein expression were seen in paired samples from individual patients.
Paired t-testing of the seven pairs of matched tumors identified two proteins with significantly different expression between brain and extracranial metastases (P<0.05 and fold change >1.5), both of which were overexpressed in the brain metastases: AKT_pS473 (P=0.0078, average fold change =2.0) and RB_pS807_S811 (P=0.0011, average fold change =1.8). AKT_pS473 expression was more than two-fold higher in the brain metastasis in five of seven paired samples (Fig. 3B) , and RB_pS807_S811 was higher in the brain metastasis in all seven pairs ( Supplementary Fig. S4 ). Three other activation-specific markers in the PI3K/AKT pathway also showed evidence of increased expression in matched brain metastases: GSK3β_pS9 (P=0.03, average fold change =1.4), GSK3α/β_pS21/S9 (P=0.16, average fold change =1.3), and PRAS40_ pT246 (P=0.18, average fold change =1.1). In contrast, PTEN protein levels were largely equivalent between matched brain and extracranial metastases (Fig. 3C) . Notably, in In the unsupervised clustering analysis of all proteins assessed by RPPA, AKT_pT308, AKT_pS473, GSK3β _pS9, GSK3α/β_pS21/S9, and PRAS40_pT246 were tightly clustered ("PI3K/AKT pathway" in Fig. 3A) , and thus likely together represent the PI3K/AKT pathway activation signature. Unsupervised clustering of the full cohort of 29 samples by the expression of these five phospho proteins showed that eight of the nine brain metastases (89%) exhibited increased activation of the PI3K/AKT pathway, which was significantly more frequent than was observed in the extracranial metastases (six of 20, 30%, P=0.0052 by Fisher's exact test) (Fig.   3D ).
Immunohistochemistry
Immunohistochemistry (IHC) assay was used to evaluate key findings from the high-throughput analyses in a larger set of matched tumors, and to confirm that detected differences were observed in tumor cells. PTEN expression by IHC was scored as Absent (<10% of cells with staining equivalent to internal positive controls, Supplementary Fig. S5 ) or Present (≥10%) based on a previous analysis that showed that complete loss of PTEN correlated with increased expression of P-AKT (34). Overall, PTEN IHC was performed on 20 pairs of matched brain and extracranial metastases. The results showed that 5% of patients had brain metastasis-only PTEN loss, while 10% of patients had extracranial metastasis-only PTEN loss (Fig. 4A) .
As a previous report had already evaluated P-AKT IHC in matched brain and extracranial metastases (20) , and RPPA analysis demonstrated that two different antibodies detected significantly increased phosphorylation of the AKT-substrate GSK3 in brain metastases, the expression of GSK3α/β_pS21/S9 was evaluated by IHC. Analysis of the intensity of (37) . Whole exome sequencing of tumors collected after progression on selective BRAF inhibitors also identified somatic alterations predicted to activate the PI3K/AKT pathway that were not detected in pre-treatment samples from the same patients in 22% of the samples, thus also implicating the pathway in acquired resistance (38) . Activation of the PI3K/AKT pathway via compensatory signaling through receptor tyrosine kinases (RTKs) has also been observed to correlate with de novo and acquired resistance in BRAF-mutant cell lines and clinical samples treated with BRAF or MEK inhibitors (28, 39, 40) . Notably, upregulation of RTK signaling can be mediated by epigenetic or tumor microenvironment-driven mechanisms (41, 42 
mediates BRAF inhibitor resistance further supports the rationale for clinical testing of combined inhibition of both MAPK and PI3K/AKT pathways in melanoma.
Previously we identified significantly higher expression of multiple activation-specific markers in the PI3K/AKT pathway in the brain metastases (N=10) than in the liver (N=5) or lung (N=5) metastases in a pilot study using RPPA (17) . The lack of paired metastases in that study made it unclear whether this result was brain metastasis specific, or reflected a generalized phenotype of patients who develop brain metastases. Studies are ongoing to assess the power of PI3K/AKT pathway activation to predict risk of brain metastasis development, and the results of our current study do not preclude a positive correlation. However, the proteomic analysis of the cohort of loss in three of nine patients, consistent with the finding that differential PTEN loss is present in only a subset of patients with evidence of increased P-AKT (20) . As our study did not include whole-exome analysis of mutational events, we cannot exclude the possibility that other mutations or CNVs could be present in the brain metastases that result in increased PI3K/AKT pathway activation. Such analyses will be performed in the future. However, an alternative hypothesis is that the activation of the PI3K/AKT pathway could be due, at least in part, to interactions between the tumor cells and the tumor microenvironment in the brain. Previously published preclinical experiments showed that the brain TME may induce significant changes in gene expression in melanoma cells (43) . In addition, astrocyte-conditioned media strongly increased P-AKT and invasiveness in melanoma cells, while fibroblast-conditioned media had minimal effect in a separate study (20) . These results support that the observed increased activation of PI3K/AKT in brain metastases could be induced by extrinsic factors in the brain microenvironment instead of by intrinsic factors in the tumor cells.
The observed activation of the PI3K/AKT pathway in brain metastases suggests this pathway as a therapeutic target. In a pilot study, we observed that treatment with the PI3K inhibitor BKM120 improve the survival of mice bearing intracranial tumors of the BRAF mutant, PTENintact human melanoma cell line A375 in a dose-dependent manner (Supplementary Fig. S8A ).
Combined treatment with BKM120 and the BRAF inhibitor LGX818 also improved survival compared to treatment with LGX818 alone (Supplementary Fig. S8B ). However, Western blotting of untreated tumors showed that the levels of AKT_pS473 were not increased in A375 brain metastases as compared to subcutaneous tumors, in contrast to the consistent increase observed in patients (Supplementary Fig. S9 ). Thus, although the observed effects are promising, additional melanoma cell lines and metastatic sites are currently being evaluated to determine if models can be identified that recapitulate the differences observed in patients for further therapeutic testing.
In conclusion, our study represents to our knowledge the first concurrent profiling of DNA hotspot mutations, DNA copy number variations, mRNA expression patterns, and protein network activation in clinical samples of patient-matched brain and extracranial metastases of any tumor type. This analysis has found overall similarity in the majority of molecular features of matching melanoma brain and extracranial metastases. However, the results provide additional evidence that increased PI3K/AKT pathway activation is a feature of brain metastases.
These results add to our understanding of the status of the PI3K/AKT pathway in melanoma and support the rationale for further testing of this pathway as a therapeutic target in this disease. 
